Is the Wnt/β-catenin pathway involved in the anti-inflammatory activity of glucocorticoids in spinal cord injury?

NeuroReport

Volumn 27, Issue 14, 2016, Pages 1086-1094

  Libro, Rosaliana ^a   Giacoppo, Sabrina ^a   Bramanti, Placido ^a   Mazzon, Emanuela ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

glucocorticoids; methylprednisolone sodium succinate; mometasone furoate; peroxisome proliferator activated receptor ; spinal cord injury; Wnt catenin pathway

Indexed keywords

BETA CATENIN; INTERLEUKIN 1BETA; METHYLPREDNISOLONE SODIUM SUCCINATE; MOMETASONE FUROATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR; WNT PROTEIN; ANTIINFLAMMATORY AGENT; CATENIN; GLUCOCORTICOID;

ADULT; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOWN REGULATION; LAMINECTOMY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN DISEASE; SPINAL CORD COMPRESSION; SPINAL CORD INJURY; TREATMENT OUTCOME; WEIGHT REDUCTION; WNT SIGNALING PATHWAY; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MYELITIS; PHYSIOLOGY; WNT SIGNALING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BODY WEIGHT; CATENINS; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; INTERLEUKIN-1BETA; MALE; METHYLPREDNISOLONE HEMISUCCINATE; MICE; MOMETASONE FUROATE; MYELITIS; SPINAL CORD INJURIES; TUMOR NECROSIS FACTOR-ALPHA; WNT SIGNALING PATHWAY;

EID: 84981484245     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0000000000000663     Document Type: Article

References (29)

1. Ille F, Atanasoski S, Falk S, Ittner LM, Märki D, Büchmann-Møller S, et al. Wnt/BMP signal integration regulates the balance between proliferation and differentiation of neuroepithelial cells in the dorsal spinal cord. Dev Biol 2007; 304:394-408.
2. Swafford D, Manicassamy S. Wnt signaling in dendritic cells: its role in regulation of immunity and tolerance. Discov Med 2015; 19:303-310.
3. Marchetti B, Pluchino S.Wnt your brain be inflamed? Yes, itWnt!. Trends Mol Med 2013; 19:144-156.
4. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 2008; 4:68-75.
5. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012; 149:1192-1205.
6. Bek S, Kemler R. Protein kinase CKII regulates the interaction of betacatenin with alpha-catenin and its protein stability. J Cell Sci 2002; 115 (Pt 24):4743-4753.
7. Jansson EA, Are A, Greicius G, Kuo IC, Kelly D, Arulampalam V, Pettersson S. The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. Proc Natl Acad Sci USA 2005; 102:1460-1465.
8. Ajmone-Cat MA, DUrso MC, di Blasio G, Brignone MS, de Simone R, Minghetti L. Glycogen synthase kinase 3 is part of the molecular machinery regulating the adaptive response to LPS stimulation in microglial cells. Brain Behav Immun 2016; 55:225-235.
9. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007; 28:551-558.
10. Gonzalez-Fernandez C, Fernandez-Martos CM, Shields SD, Arenas E, javier Rodriguez F. Wnts are expressed in the spinal cord of adult mice and are differentially induced after injury. J Neurotrauma 2014; 31:565-581.
11. Hugenholtz H, Cass DE, Dvorak MF, Fewer DH, Fox RJ, Izukawa DM, et al. High-dose methylprednisolone for acute closed spinal cord injury - only a treatment option. Can J Neurol Sci 2002; 29:227-235.
12. Samano C, Kaur J, Nistri A. A study of methylprednisolone neuroprotection against acute injury to the rat spinal cord in vitro. Neuroscience 2016; 315:136-149.
13. Harrop JS. Spinal cord injury: debating the efficacy of methylprednisolone. Neurosurgery 2014; 61 (Suppl 1):30-31.
14. Passali D, Spinosi MC, Crisanti A, Bellussi LM. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med 2016; 11:18.
15. Ayroldi E, Cannarile L, Migliorati G, Nocentini G, Delfino DV, Riccardi C. Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways. FASEB J 2012; 26:4805-4820.
16. Galuppo M, Rossi A, Giacoppo S, Pace S, Bramanti P, Sautebin L, Mazzon E. Use of Mometasone furoate in prolonged treatment of experimental spinal cord injury in mice: A comparative study of three different glucocorticoids. Pharmacol Res 2015; 99:316-328.
17. Barton BE, Jakway JP, Smith SR, Siegel MI. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol 1991; 13:251-261.
18. Bijsmans ITGW, Guercini C, ramos Pittol JM, OmtaW, Milona A, Lelieveld D, et al. The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression. Sci Rep 2015; 5:14086.
19. Beurel E. Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. Front Mol Neurosci 2011; 4:18.
20. Chawla A. Control of macrophage activation and function by PPARs. Circ Res 2010; 106:1559-1569.
21. Wada K, Nakajima A, Blumberg RS. PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohns disease. Trends Mol Med 2001; 7:329-331.
22. Liu H, Rose ME, Culver S, Ma X, Dixon CE, Graham SH. Rosiglitazone attenuates inflammation and CA3 neuronal loss following traumatic brain injury in rats. Biochem Biophys Res Commun 2016; 472:648-655.
23. Palma A, Sainaghi PP, Amoruso A, Fresu LG, Avanzi G, Pirisi M, Brunelleschi S. Peroxisome proliferator-activated receptor-gamma expression in monocytes/macrophages from rheumatoid arthritis patients: relation to disease activity and therapy efficacy-a pilot study. Rheumatology (Oxford) 2012; 51:1942-1952.
24. Esposito E, Cuzzocrea S. Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury. Expert Opin Ther Targets 2011; 15:943-959.
25. Park SW, Yi JH, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, Vemuganti R. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007; 320:1002-1012.
26. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001; 7:41-47.
27. Li X, Du J, Xu S, Lin X, Ling Z. Peroxisome proliferator-activated receptor-? agonist rosiglitazone reduces secondary damage in experimental spinal cord injury. J Int Med Res 2013; 41:153-161.
28. Zhang Q, Hu W, Meng B, Tang T. PPAR? agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res 2010; 32:852-859.
29. Zhang Q, Huang C, Tang T, Shi Q, Yang H. Comparative neuroprotective effects of methylprednisolone and rosiglitazone, a peroxisome proliferatoractivated receptor-? following spinal cord injury. Neurosciences (Riyadh) 2011; 16:46-52.